{"id":"NCT04673786","sponsor":"Celltrion","briefTitle":"A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis","officialTitle":"A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-11","primaryCompletion":"2021-08-04","completion":"2022-05-12","firstPosted":"2020-12-17","resultsPosted":"2023-06-05","lastUpdate":"2023-06-05"},"enrollment":509,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P43","otherNames":[]},{"type":"BIOLOGICAL","name":"Stelara","otherNames":[]}],"arms":[{"label":"CT-P43","type":"EXPERIMENTAL"},{"label":"Stelara","type":"ACTIVE_COMPARATOR"}],"summary":"This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"The Mean Percent Improvement From Baseline in PASI Score at Week 12","timeFrame":"From baseline to Week 12","effectByArm":[{"arm":"CT-P43","deltaMin":77.93,"sd":1.771},{"arm":"EU-Stelara","deltaMin":75.89,"sd":1.739}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Estonia"]},"refs":{"pmids":["37991693"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":256},"commonTop":["COVID-19","Upper respiratory tract infection","Latent tuberculosis","Alanine aminotransferase increased","Aspartate aminotransferase increased"]}}